



# Innofect

## Company Overview

Innofect is proposing a device to be deployed in multiple locations throughout a clinical setting to disinfect the hands of healthcare personnel with a brief application of its proprietary hand sanitizing solution. The approach will lead to high levels of compliance behavior by being simple, dry, quick, non-irritating to the skin, and effective against antibiotic resistant organisms.

## Problem

Hospitals and other medical facilities are at the forefront of the struggle against the emergence of antibiotic resistance in pathogenic microorganisms. They are nexuses between those who are already infected with resistant organisms and those who are most vulnerable to acquiring new infections. Moreover, the antibiotic treatments administered in hospitals create selective pressure for new and higher levels of resistance. As a consequence, hospital-acquired “nosocomial” infections with highly resistant organisms are increasingly common, expensive, and deadly. The estimated cost of treating hospital-acquired infections is \$31 billion per year, with more than one third of these infections being preventable.

## Solution

Innofect proposes an entirely new means of approaching the problem of nosocomial infections by a specially patented device for application of the proprietary hand sanitization solution. Presently, there are no alternatives to handwashing and alcohol-based hand sanitizers (ABHS) for hand disinfection. This new sanitizing technique addresses the chief problems that have caused handwashing and ABHS to fail – most significantly, the intolerance of human skin for frequent treatments, the dependence on personal technique for effectiveness, and the aversion of medical staff to the notion that they are unclean.

Innofect’s device is deployable in multiple locations throughout a healthcare setting to disinfect the hands of healthcare personnel with a brief application of the hand sanitization solution. These devices are inexpensive to install, and the method of disinfection is fast, dry, and non-irritating to the skin even with frequent use. Employing this technique can prevent hospital-acquired infections.

## Team Information

**Tim Shaffer**, President/CEO, is a strategic business executive with expertise in technology transfer, operational leadership, product commercialization, fundraising, and business development. He holds a Master of Science in Organizational Dynamics, an Executive Master’s in Technology Management, and a Master of Philosophy all from the University of Pennsylvania.

**Paul Axelsen**, MD, Founder is a Professor of Pharmacology, Biochemistry, Biophysics, and Medicine at the University of Pennsylvania Perelman School of Medicine. Dr. Axelsen is board certified in both Internal Medicine and Infectious Diseases. His clinical experience has included the Immunodeficiency Program at Penn as a clinical HIV/AIDS specialist.

For more information, please contact Tim Shaffer at [tshaffer@innofect.net](mailto:tshaffer@innofect.net).